These results suggested that FATP2 inhibition could effectively decrease NLRP3 inflammasome activation in MDSCs and IL-17 production in CD4+ T cells during fatty liver IRI, which paved the way to study the effects of FATP2 blockade on tumour recurrence post transplantation. Here, CD4 is linked to neoplasm.